EXEL
HEALTHCAREExelixis Inc
$48.70+4.28 (+9.64%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving EXEL Today?
No stock-specific AI insight has been generated for EXEL yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$33.76$49.62
$48.70
Fundamentals
Market Cap$11.6B
P/E Ratio15.3
EPS$3.02
Dividend Yield—
Dividend / Share—
ROE0.4%
Profit Margin0.4%
Debt / Equity—
Trading
Volume6.3M
Avg Volume (10D)—
Shares Outstanding251.4M
EXEL News
21 articles- Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in MayYahoo Finance·May 7, 2026
- Why Exelixis (EXEL) Is Up 9.0% After Strong Q1 2026 Earnings And New Buyback ProgramYahoo Finance·May 7, 2026
- Exelixis Seen Trading Steady on Modest Drug Growth, RBC SaysYahoo Finance·May 6, 2026
- EXEL Q1 Earnings Top Estimates, Colorectal Cancer Drug in FocusYahoo Finance·May 6, 2026
- Exelixis, Inc. Q1 2026 Earnings Call SummaryMoby·May 6, 2026
- Exelixis Q1 Earnings Call HighlightsMarketbeat·May 5, 2026
- Exelixis (EXEL) Q1 2026 Earnings TranscriptMotley Fool·May 5, 2026
- Exelixis (EXEL) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesYahoo Finance·May 5, 2026
- Exelixis (EXEL) Tops Q1 Earnings EstimatesYahoo Finance·May 5, 2026
- Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate UpdateYahoo Finance·May 5, 2026
- Assessing Exelixis (EXEL) Valuation After Mixed Share Performance And CABOMETYX Growth NarrativeYahoo Finance·May 2, 2026
- Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseYahoo Finance·Apr 28, 2026
- Pancreatic Neuroendocrine Tumors Market Research Report 2025-2035, Competitive Analysis of Key Players - Novartis, Pfizer, Exelixis, Merck, Ipsen Pharma, and Takeda PharmaYahoo Finance·Apr 28, 2026
- Why Dow Jones Stock Merck Skidded 4% — And Boosted A Key RivalYahoo Finance·Apr 21, 2026
- Exelixis to Release First Quarter 2026 Financial Results on Tuesday, May 5, 2026Yahoo Finance·Apr 21, 2026
- Why Is Merck Stock Falling Tuesday?Benzinga·Apr 21, 2026
- Assessing Exelixis (EXEL) Valuation After Recent Short Term Share Price PressureYahoo Finance·Apr 17, 2026
- 3 Under-the-Radar Healthcare Stocks Worth Adding to Your WatchlistMotley Fool·Apr 16, 2026
- Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report?Yahoo Finance·Apr 16, 2026
- Kidney Cancer Drugs Market to Grow by $2 Billion During 2026-2030: Pfizer, Novartis, Exelixis, Roche, Bristol Myers Squibb Company, and Bayer Lead the IndustryYahoo Finance·Mar 31, 2026
- Lilly’s AI commitment expands through deal with InsilicoBiopharmadive·Mar 30, 2026
All 21 articles loaded
Price Data
Open$44.00
Previous Close$44.42
Day High$44.30
Day Low$43.50
52 Week High$49.62
52 Week Low$33.76
52-Week Range
$33.76$49.62
$48.70
Fundamentals
Market Cap$11.6B
P/E Ratio15.3
EPS$3.02
Dividend Yield—
Dividend / Share—
ROE0.4%
Profit Margin0.4%
Debt / Equity—
Trading
Volume6.3M
Avg Volume (10D)—
Shares Outstanding251.4M
About Exelixis Inc
Exelixis, Inc., an oncology-focused biotechnology company, is focused on the discovery, development, and commercialization of new drugs to treat cancers in the United States. The company is headquartered in Alameda, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—